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LETTERS
Previously reported babesiosis 
cases in children have been mostly 
acquired by blood transfusion (10). 
The patient had no history of trans-
fusions with blood products and had 
never traveled outside his home town 
before disease onset. Although he 
and his parents did not recall any tick 
bites, he was at high risk for expo-
sure to ticks because he often played 
with his dog, which frequently went 
outdoors in a tick-infested forested 
area. The dog may have transmitted a 
Babesia sp.–infected tick to the pa-
tient. However, ticks from the dog 
were not available for identification 
and testing.
The patient in our study was pre-
sumed to be healthy and immunocom-
petent, which indicates that Babesia 
species can cause infections even in 
healthy persons. Babesiosis should be 
considered in the differential diagno-
sis of patients with a history of tick 
exposure and prolonged and irregu-
lar fever. Blood smear evaluation for 
intraerythrocytic parasites should be 
considered.
The patient was treated with 
azithromycin and atovaquone and the 
parasites were cleared within 1 month. 
This combined treatment was well 
tolerated and effective, and it can be 
recommended as an alternative treat-
ment to the commonly used therapy of 
quinine and clindamycin (1).
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and Klebsiella  
pneumoniae in 
Gulls, Alaska, USA
To the Editor: Resistance to 
β-lactam antibacterial drugs has spread 
rapidly, particularly through the CTX-
M β-lactamase enzymes (CTX-M) (1). 
Although CTX-Ms are geographically 
widely distributed, reports of extended-
spectrum β-lactamase (ESBL) dissem-
ination are few from remote regions. 
In 2008, we reported phenotypic resis-
tance traits in Escherichia coli isolates 
in 8.2% of wild birds sampled in the 
Arctic (2). We sampled approximately 
260 wild birds, mainly gulls and geese, 
but found no ESBL-harboring isolates 
(J. Bonnedahl et al., unpub. data). Here 
we report results of our 2010 study at 
Barrow, Alaska, USA, a follow up to 
our 2005 study in which we found van-
comycin-resistant enterococci (VRE) 
with clear traits of human origin in 
glaucous gulls (3). Our findings show 
a remarkable change, not in VRE dis-
semination, which is fairly unchanged, 
but in the emergence of ESBLs and 
general resistance of E. coli isolates.
We collected 150 fecal samples 
from a population of adult gulls resid-
ing close to a landfill site. For a de-
scription of general resistance levels 
(4,5), susceptibility of 1 randomly se-
lected E. coli isolate per sample (137 
isolated from 150 samples) was test-
ed to a set of 10 antibacterial agents. 
Nearly half (48%) of the 137 E. coli 
isolates were resistant to at least 1 of 
the drugs tested. Resistance to 1 or 
2 antimicrobial agents was found in 
32% and 13% of the tested isolates, 
respectively, and resistance to >3 
was found in 3% of isolates (online 





We analyzed samples for presence 
of VRE (3). Seven (4.7%) E. faecium 
isolates were found, all of which har-
bored both the vanA and the esp genes 
(found in isolates of the CC17 lineage) 
(3). No other VRE were found.
To investigate the presence of 
ESBL-producing bacteria, we con-
ducted a selective screen as described 
(6). ESBL-producing bacteria were 
found (E. coli and K. pneumoniae), 
and ESBL genes (blaCTX-M, blaSHV, 
and blaTEM) in ESBL-positive isolates 
were analyzed (6). We found 33 E. 
coli and 35 K. pneumoniae ESBL-
producing isolates in 55 samples (12 
samples had >1 unique isolate), a to-
tal of 37% of ESBL-harboring sam-
ples (Table).
We performed multi-locus se-
quence typing (MLST) on ESBL-
producing E. coli isolates (4). Isolates 
were of described sequence types 
(STs) (ST131 [12 isolates], ST38 [10], 
ST405 [3], and ST10 [1]), and of pre-
viously undescribed STs (designated 
ST2253 [1 isolate] and ST2967 [6 iso-
lates]) (Table).
In our 2005 study in Barrow, gen-
eral resistance was relatively low, and 
no ESBL was found; surprisingly, how-
ever, 2 VRE isolates of a human clonal 
lineage were found (3; M. Drobni et al., 
unpub. data). Since then, resistance dis-
semination, particularly that of ESBLs, 
has exploded globally (1). In 2010, we 
found a high level of general resistance; 
48% of randomly selected E. coli iso-
lates displayed resistance toward >1 
antibacterial drugs. This level is similar 
to the level we found in gulls in France 
in 2008, an area with high current and 
historical clinical antibacterial drug 
use and where birds have close contact 
with human activities (4).
We screened samples for VRE 
and ESBL-producing bacteria. The 
prevalence of VRE decreased from 
6% in 2005 to 4.7% in the current 
study (3), indicating a slow decline or 
stability in VRE. ESBL, on the other 
hand, was not found in the 2005 study 
(M. Drobni et al., unpub. data) but 
emerged in 37% of samples carrying 
E. coli and/or K. pneumoniae harbor-
ing ESBLs. In the study from France, 
only 9.4% of birds carried ESBLs (4), 
although a study of gulls in Portugal 
during 2007–2008 reported an ESBL 
carriage of 32% (7), more similar to 
results of our current study but in con-
trast also because they investigated 
gulls from a highly populated area.
E. coli isolates mainly carried 
blaCTX-M-14 or blaTEM-19, whereas K. 
pneumoniae isolates mainly carried 
blaCTX-M-15, blaSHV-12, or blaSHV-102. To 
our knowledge, ESBLs in E. coli and 
K. pneumoniae have not been reported 
from Alaska, but in two 10-year per-
spective reports from Canada (8,9), 
similar patterns and genotypes are re-
ported in E. coli and K. pneumoniae in 
clinical isolates (mainly from samples 
of persons with urinary tract infections 
and urosepsis). Our MLST of E. coli 
indicated 4 known STs; ST10, ST38, 
ST131, and ST405, all very common 
in the material from Canada (8), and 
major STs responsible for CTX-M dis-
semination worldwide (1). Two novel 
STs were found; several isolates were 
designated to 1 of them. We conclude 
that the relatively limited variation in 
clonal variants (STs) and ESBL geno-
types is a consequence of recent intro-
duction from connecting areas, such 
as Canada, possibly directly by bird 
migration or human activities, of a 
few resistant clones, followed by a lo-
cal clonal expansion. This conclusion 
is supported by our 2005 study show-
ing no ESBLs and by studies showing 
where different clones might have been 
introduced continuously for long peri-
ods, such as our study in France (4), 
which display a much larger diversity.
The dissemination of ESBLs to 
Barrow is part of this global pattern, 
and it is safe to say that humans and 
wildlife share resistant E. coli flora. 
When areas such as remote parts of 
Alaska are affected, global coverage 
is imminent.
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Table.	Characterization	of	Escherichia coli and	Klebsiella pneumoniae ESBL-producing	
isolates,	Barrow,	Alaska,	USA* 
Isolates,	no.† 
bla genotype  
MLST	profile CTX-M SHV TEM  
E. coli      
 12 14 – 1  ST38	(ST2253)‡ 
 11 14 – –  ST131	(ST10)§ 
 5 – – 19  ST2967¶ 
 3 27 – –  ST405 
 1 15 – –  ST131 
 1 – – 1  ST2967¶ 
K. pneumoniae      
 4 15 12 1  ND 
 5 – 12 1  ND 
 2 – 12 –  ND 
 2 – 102 19  ND 
 8 – 102 –  ND 
 1 – – 19  ND 
 4 15 1 1  ND 
 1 – 2 –  ND 
*ESBL,	extended-spectrum	-lactamase;	MLST,	multilocus	sequence	type;	ST,	sequence	type;	ND,	
no	data. 
†E. coli comprised	33	isolates	from	32	samples.	K. pneumoniae comprised	35	isolates	from	35	
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mecC Gene in  
Animals and Urban 
Wastewater, Spain
To the Editor: A new methicillin 
resistance mechanism gene, a diver-
gent mecA homologue named mecC 
(formerly mecALGA251), was recently 
described in Staphylococcus aureus 
(1). Methicillin-resistant S. aureus 
(MRSA) isolates carrying mecC have 
been recovered from humans, rumi-
nants, pets, and other animals such 
as rats, seals, and guinea pigs (1–3). 
It has been suggested that mecC-car-
rying MRSA isolates might not be de-
tected by using MRSA selective me-
dia (4). For mecC-carrying S. aureus 
isolates, cefoxitin MICs of 4–64 mg/L 
have been demonstrated (1–2,4), val-
ues that would normally include sus-
ceptible isolates, according to the epi-
demiologic cutoff value established by 
the European Committee on Antibi-
otic Susceptibility Testing (EUCAST; 
www.eucast.org). mecC-carrying S. 
aureus isolates have been classified 
as heteroresistant (5), and MICs can 
be affected by the drug-susceptibility 
testing method used (1,5).
These observations led us to 
retrospectively investigate the pres-
ence of mecC gene in a set of 361 
mecA-negative S. aureus isolates 
collected during 2009–2012 (Table), 
independently of their susceptibility 
to cefoxitin. Isolates were recovered 
from healthy carriers in livestock (n 
= 39), from wild animals (n = 254), 
and from wastewater (effluents) from 
an urban sewage plant (n = 68). Spe-
cific amplification of the mecC gene 
was performed as described (6). The 
mecC-carrying S. aureus isolates were 
tested by broth microdilution using 
Microtiter EUST plates (Trek Diag-
nostic Systems, East Grinstead, UK) 
for susceptibility to benzylpenicillin, 
cefoxitin, chloramphenicol, cipro-
floxacin, clindamycin, erythromycin, 
florfenicol, fusidic acid, gentamicin, 
kanamycin, linezolid, mupirocin, ri-
fampin, sulfamethoxazole, strepto-
mycin, quinupristin-dalfopristin, tet-
racycline, thiamulin, trimethoprim, 
and vancomycin. Additionally, sus-
ceptibility to oxacillin was determined 
by using microScan Gram Positive 
Combo panel 37 (Siemens, Erlangen, 
Germany). MICs were interpreted ac-
cording to EUCAST epidemiologic 
cutoff values.
mecC was detected in a total of 4 
isolates from wild boar (n = 1), fallow 
deer (n = 2), and urban wastewater (n 
= 1); these isolates represent 1% of 
the 361 tested isolates. The 3 isolates 
recovered from animals were suscep-
tible to all antimicrobial drugs tested 
other than β-lactams and to oxacillin 
(MICs 0.5–1 mg/L) but were resistant 
to penicillin (MICs 0.5–2 mg/L). Two 
of the isolates were resistant to cefoxi-
tin (MICs 8 and 16 mg/L) and the third 
was susceptible (MIC 4 mg/L). The 
wastewater isolate was resistant to 
penicillin (MIC 2 mg/L) and erythro-
mycin (MIC 16 mg/L) and susceptible 
to all other antimicrobial drugs tested, 
including cefoxitin (MIC 4 mg/L) and 
oxacillin (MIC ≤0.25 mg/L).
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